TGFB1 and cancer: In several cancer types, clinical trials have been initiated to target specific genes associated with key signaling pathways known to contribute to radioresistance, including the ERK/MAPK, Wnt/β-catenin, TGF-β/SMAD, and PI3K-AKT pathways.